Clinical trial NCT05465655: Cara CDRM (Conduction Disturbance Risk Monitor) 2.0
Official title: Pilot Study to Estimate a Reduction of TAVR Associated Conduction Disturbance Through Notification of Cara Monitor During TAVR Procedure
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Transcatheter Aortic Valve Replacement
Lead sponsor: Cara Medical Ltd
Sponsor class: INDUSTRY
First posted: 2022-07-20
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Prospective, multicenter, roll-in, pilot clinical trial.

Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed for New-Onset Conduction Disturbances (NOCD).

The study will be conducted in two stages:

During the first roll-in stage of the study, 50 intended to undergo TAVR (all comers) will be enrolled.

Data will be collected according to the study schedule below of pre-, during and after the TAVR procedure up to 14 days FU.

This data for the first 50 patients will be analyzed to evaluate the ability of the Cara Monitor prediction of NOCD post TAVR.

The second stage of the stage will be conducted upon completion of the first stage analysis and will be considered to randomize 1:1 the subjects connected to Cara Monitor during the procedure versus site-specific current practice.

The effect of Cara Monitor on reduction of NOCD post TAVR compared to patients treated and followed per regular site-specific practice will be estimated.

Detailed description: Data to be collected during the study procedure for both stages:

1. Pre-procedure:

   1. Demographics, medical history, cardiac history, medications
   2. Cardiac CT raw data to be collected from all the pre-procedure CT scans performed in Medical Centers and from out-of-hospital sources (if available).
   3. In hospital 12 lead ECG
2. Procedure:

   During the procedure, the 12 lead ECG will be recorded processed, and displayed on the Cara monitor that is connected to Norav NR-1207-3 ECG Holter System. The Hemodynamic and Fluoroscopy monitors will be recorded on a commercially available video recorder.
3. Post-procedure (in hospital)

   1. After the procedure patients will continue to be connected to a commercially available to a commercially available 14 days ambulatory Holter monitor (AEM) (e.g. Bittium Faros™ ; MoMe™ Kardia) and will remain with the patient after the discharge for 14 days.
   2. Hospital standard 12 lead ECG will be recorded after the procedure, downloaded and collected by the study team.
4. Post-procedure - out of hospital:

   At discharge, patients will stay connected to the ambulatory Holter monitor (AEM) (Bittium Faros™; MoMe™ Kardia ) for 14 days post-procedure. Holter will be collected from patients at the end of the 14-day recording and its data downloaded and collected.

   Patients will be followed according to the current medical practice.
5. Follow-up according to the current medical practice a. 30 days follow-up hospital visit: i. Cardiac echo (if available) ii. 12 lead ECG b. 6 month - Clinical FU phone call c. 12 months Clinical FU phone call

Conduction Disturbances (CD) outcome will be subdivided into:

1. PPM or High-Grade AV Block (HGAVB)
2. All other new onset (or deterioration) of CD that are not listed in #1
3. No new onset CD

Eligibility criteria: Inclusion Criteria:

1. Must meet be ≥ 18 years of age.
2. Must meet indications for TAVR using approved devices
3. Provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
4. Willing to comply with specified follow-up evaluations.
5. Must meet the legal minimum age to provide Informed Consent based on local regulatory requirements.

Exclusion Criteria:

1. Any implanted device or an indication for treatment with rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
2. Any contraindication to the TAVR procedure according to the instructions for use.
3. Less than the legal age of consent, legally incompetent, or otherwise vulnerable.
4. Planned treatment with any other investigational device, drug, or procedure (excluding registries) during the study period.

Primary outcomes:
measure: Evaluate Cara performance in reduction of New Onset Conduction Disturbances (NOCD)
timeFrame: 14 days
measure: Evaluate Cara performance in reduction of Permanent Pacemaker (PPM) or High-Grade AV Block (HGAVB)
timeFrame: 14 days
measure: Evaluate Cara usability using a dedicated questioner
timeFrame: 1 Day of Procedure
measure: Evaluate Cara Safety, collecting Adverse Events
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mackram F. Eleid, M.D.
state: Minnesota
Study officials:
affiliation: Cara Medical Ltd
name: Helena Grinberg, PhD
role: STUDY_CHAIR
References: